{"id":61133,"date":"2024-02-28T07:26:13","date_gmt":"2024-02-28T07:26:13","guid":{"rendered":"https:\/\/medsname.com\/venish-sr\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"venish-sr","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/venish-sr\/","title":{"rendered":"Venish SR"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Venish SR?<\/h3>\n
\n

Venish SR<\/strong> bevat venlafaxine ER (37.5 \/ 75 \/ 150 mg ER)<\/strong> from a WHO-GMP certified manufacturer (Healing Pharma) — an SNRI<\/strong> with broad evidence in depression and anxiety-spectrum disorders. Standard start: 75 mg once daily<\/strong> with food; titrate to 150–225 mg\/day for full SNRI activity (max 375 mg in MDD, 225 mg in GAD\/social anxiety\/panic). Onset: 2–4 weeks. Below 150 mg the drug behaves mostly as an SSRI; norepinephrine reuptake inhibition appears at higher doses. Important<\/strong>: dose-dependent blood-pressure rise<\/strong> (BP must be monitored at > 225 mg). Has a severe discontinuation syndrome<\/strong> — mandatory taper. More dangerous in overdose than SSRIs (cardiac toxicity, seizures).<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> Venish SR is a serotonin-norepinephrine reuptake inhibitor (SNRI)<\/strong>, prescribed and titrated over weeks for major depressive disorder (MDD), generalised anxiety disorder (GAD), social anxiety disorder, and panic disorder<\/strong>. It is niet<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — suicidality.<\/strong> All antidepressants carry an FDA black-box warning for increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 25, particularly during the first weeks of treatment or after dose changes. Family members and prescribers should monitor closely for worsening mood, agitation, or suicidal ideation in this age group.<\/div>\n

What Is Venish SR?<\/h2>\n

Venish SR is an oral extended-release tablet\/capsule of venlafaxine (37.5 \/ 75 \/ 150 mg ER)<\/strong> manufactured by Healing Pharma under WHO-GMP certification. Venlafaxine (US brand Effexor XR<\/strong>) is the prototype serotonin-norepinephrine reuptake inhibitor (SNRI)<\/strong>. It blocks both the serotonin transporter (SERT) at lower doses and the norepinephrine transporter (NET) at higher doses, producing a dose-dependent shift from SSRI-like to SNRI-like pharmacology.<\/p>\n

It is a first-line option in NICE and APA guidelines for major depression and is one of the most-evidenced antidepressants for generalised anxiety disorder.<\/p>\n

Goedgekeurde indicaties<\/h2>\n
    \n
  • Major depressive disorder (MDD)<\/strong> — including treatment-resistant depression at higher doses<\/li>\n
  • Generalised anxiety disorder (GAD)<\/strong><\/li>\n
  • Social anxiety disorder (chronic \/ generalised)<\/strong><\/li>\n
  • Panic disorder<\/strong> — with and without agoraphobia<\/li>\n
  • Off-label: diabetic neuropathy, chronic fatigue, fibromyalgia, vasomotor symptoms of menopause<\/li>\n<\/ul>\n

    Dosering<\/h2>\n\n\n\n\n\n\n\n
    Indicatie<\/th>\nStart<\/th>\nTypical effective range<\/th>\nMaximum<\/th>\nOpmerkingen<\/th>\n<\/tr>\n<\/thead>\n
    MDD<\/td>\n75 mg\/day with food<\/td>\n150–225 mg\/day<\/td>\n375 mg\/day<\/td>\nIncrease by 75 mg every 2 weeks<\/td>\n<\/tr>\n
    GAD, social anxiety, panic<\/td>\n37.5–75 mg\/day<\/td>\n75–225 mg\/day<\/td>\n225 mg\/day<\/td>\nSlower up-titration in panic to avoid early agitation<\/td>\n<\/tr>\n
    Elderly \/ hepatic \/ renal impairment<\/td>\n37.5 mg\/day<\/td>\nUp to 75–150 mg with caution<\/td>\n\u2014<\/td>\nReduce by 25–50% in moderate hepatic impairment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Mechanism by Dose<\/h2>\n

    Pharmacology shifts as dose climbs<\/h2>\n\n\n\n\n\n\n\n\n
    Dagelijkse dosis<\/th>\nPharmacology<\/th>\nClinical relevance<\/th>\n<\/tr>\n<\/thead>\n
    37.5–75 mg<\/td>\nPredominantly serotonergic (SSRI-like)<\/td>\nUseful as a starting \/ sub-therapeutic dose for tolerability<\/td>\n<\/tr>\n
    75–150 mg<\/td>\nMostly serotonergic with emerging noradrenergic activity<\/td>\nLower end of antidepressant efficacy range<\/td>\n<\/tr>\n
    150–225 mg<\/td>\nCombined SERT + NET inhibition (true SNRI)<\/td>\nStandard effective dose for most adults; full SNRI benefit<\/td>\n<\/tr>\n
    225–375 mg (MDD only)<\/td>\nStrong SERT + NET inhibition<\/td>\nUsed in treatment-resistant depression; BP and cardiac monitoring required<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Bijwerkingen<\/h2>\n

    Common, persistent, and rare side effects<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Frequentie<\/th>\nEffect<\/th>\nNotes \/ management<\/th>\n<\/tr>\n<\/thead>\n
    Vaak voorkomend<\/td>\nNausea (dose-dependent)<\/td>\nTake with food; usually subsides over 1–2 weeks<\/td>\n<\/tr>\n
    Vaak voorkomend<\/td>\nHoofdpijn, duizeligheid<\/td>\nTransient; adequate hydration<\/td>\n<\/tr>\n
    Vaak voorkomend<\/td>\nInsomnia or somnolence<\/td>\nOften dose in the morning if activating<\/td>\n<\/tr>\n
    Vaak voorkomend<\/td>\nDry mouth, constipation, sweating<\/td>\nSweating may persist; can be marked<\/td>\n<\/tr>\n
    Vaak voorkomend<\/td>\nSexual dysfunction<\/td>\nSimilar prevalence to SSRIs<\/td>\n<\/tr>\n
    Less common<\/td>\nIncreased blood pressure (dose-dependent)<\/td>\nCheck BP at baseline and periodically; significant rise above 225 mg\/day in 5–10% — may need dose reduction or switch<\/td>\n<\/tr>\n
    Less common<\/td>\nIncreased pulse, palpitations<\/td>\nCaution in patients with cardiac disease<\/td>\n<\/tr>\n
    Less common<\/td>\nWeight changes (modest)<\/td>\nLess weight gain than paroxetine or mirtazapine<\/td>\n<\/tr>\n
    Zeldzaam<\/td>\nHyponatraemia (SIADH)<\/td>\nOlder adults at greatest risk<\/td>\n<\/tr>\n
    Zeldzaam<\/td>\nBleeding risk<\/td>\nCaution with NSAIDs, anticoagulants<\/td>\n<\/tr>\n
    Zeldzaam<\/td>\nSerotonin syndrome<\/td>\nSee interactions<\/td>\n<\/tr>\n
    Zeldzaam<\/td>\nMydriasis \/ acute angle-closure glaucoma<\/td>\nCaution in narrow-angle glaucoma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Discontinuation Syndrome<\/h2>\n

    Venlafaxine has a short half-life<\/strong> (parent ~5 h; active metabolite desvenlafaxine ~11 h). Discontinuation symptoms are severe and rapid<\/strong>, second only to paroxetine: brain zaps, dizziness, nausea, sweating, irritability, insomnia, vivid dreams, flu-like aches. Often appear within 24–48 hours of a missed dose.<\/p>\n

    Mandatory slow taper<\/strong>: reduce by 75 mg every 2–4 weeks; below 75 mg use the smallest available capsule and consider every-other-day or hyperbolic tapering. Never stop abruptly. Patients on long-term venlafaxine often spend months on tapering — this is normal.<\/p>\n

    Geneesmiddelinteracties<\/h2>\n

    Absolute contraindications<\/strong>: MAOIs, linezolid, methylene blue. 14-day washout.<\/p>\n

    Serotonergic interactions<\/strong>: triptans, tramadol, pethidine, dextromethorphan, St John’s wort, lithium — serotonin syndrome risk.<\/p>\n

    CYP2D6 substrate<\/strong>: levels rise with strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine). Consider dose reduction.<\/p>\n

    Bleeding risk<\/strong>: NSAIDs, aspirin, warfarin, DOACs.<\/p>\n

    Cardiac and Overdose Considerations<\/h2>\n

    Venlafaxine is more dangerous in overdose than SSRIs<\/strong>: cardiac conduction abnormalities, QT prolongation, seizures, and serotonin syndrome have been reported. Provide only short supplies to patients at acute suicide risk. Pre-existing significant cardiac disease, recent MI, or uncontrolled hypertension are relative contraindications.<\/p>\n

    Veelgestelde vragen<\/h2>\n

    How long does Venish SR take to work?<\/h3>\n

    Anxiety symptoms often improve in 2–3 weeks; mood response in MDD typically appears at 4–6 weeks. Patients on sub-therapeutic doses (< 150 mg) may need dose escalation before seeing full benefit.<\/p>\n

    Why does the dose matter so much for venlafaxine?<\/h3>\n

    Below 150 mg\/day, venlafaxine acts mostly like an SSRI — norepinephrine reuptake inhibition appears only at higher doses. Patients who don’t respond at 75 mg often respond once titrated to 150 mg or above.<\/p>\n

    Will Venish SR raise my blood pressure?<\/h3>\n

    Possibly — venlafaxine causes dose-dependent BP increases. Below 150 mg the effect is small; above 225 mg, 5–10% of patients see clinically significant increases. BP should be monitored at baseline and after dose escalations.<\/p>\n

    Can I stop Venish SR abruptly?<\/h3>\n

    No — venlafaxine has one of the worst discontinuation syndromes in the antidepressant class (brain zaps, dizziness, nausea, sweating). Mandatory taper, often over months for long-term users.<\/p>\n

    Is Venish SR safe in pregnancy?<\/h3>\n

    Limited data — not the first-choice antidepressant in pregnancy. Sertraline is preferred. Late-third-trimester exposure carries a small risk of neonatal adaptation syndrome and persistent pulmonary hypertension of the newborn.<\/p>\n

    Does Venish SR cause weight gain?<\/h3>\n

    Less than paroxetine or mirtazapine. Some patients see modest weight changes; others lose weight from initial GI side effects. Less metabolic burden than antipsychotics.<\/p>\n

    Can I drink alcohol on Venish SR?<\/h3>\n

    Light, occasional alcohol is generally tolerated. Heavy alcohol use worsens depression \/ anxiety, increases sedation, and is implicated in disinhibited behaviour.<\/p>\n

    Wat gebeurt er als ik een dosis mis?<\/h3>\n

    Take it as soon as you remember unless close to the next dose. Withdrawal symptoms can begin within 24–48 hours of a missed dose — do not skip multiple doses.<\/p>\n

    How is Venish SR different from duloxetine or desvenlafaxine?<\/h3>\n

    All are SNRIs. Duloxetine has a different binding profile (more SNRI even at lower doses, hepatic concerns), is also approved for diabetic neuropathy and fibromyalgia. Desvenlafaxine is the active metabolite of venlafaxine — bypasses CYP2D6 metabolism, more predictable plasma levels.<\/p>\n

    How should Venish SR be stored?<\/h3>\n

    Store at 15–30 °C in the original blister packaging, away from moisture and sunlight. Keep out of reach of children — venlafaxine overdose is medically significant.<\/p>\n

    Medische disclaimer:<\/strong> Information on this page is intended for adults using prescribed psychiatric medication and is not a substitute for individualised medical care. Antidepressants, antipsychotics, and related medications can interact with other drugs, alcohol, and pre-existing conditions. Discuss any new medication, dose change, or planned discontinuation with a qualified prescriber. If you experience suicidal thoughts, mania, severe akathisia, signs of serotonin syndrome (high fever, confusion, muscle rigidity, rapid heart rate), or neuroleptic malignant syndrome, seek emergency care immediately.<\/div>\n

    <\/p>\n

    Gerelateerde alternatieven<\/h3>\n

    Andere producten in Chronische aandoeningen<\/strong> die klanten ook bekijken:<\/p>\n